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acute or short-term interventions could be 
not always representative of the  ‘ free-living ’ 
conditions typical of population-based 
studies such as the PREVEND Study. An 
alternative possibility is that some of the 
associations of copeptin with other varia-
bles refl ected the infl uence of determinants 
of vasopressin secretion rather than the 
eff ects of vasopressin  per se . For instance, 
data of the PREVEND Study indicated that 
the correlation coeffi   cient of plasma copep-
tin with urinary sodium  per se (a marker of 
salt intake) was substantially similar to the 
correlation coeffi  cient of plasma copeptin 
with overall urine osmolarity calculated on 
the basis of the urinary concentrations of 
sodium and other osmolytes. 1 
 Meijer  et al. 1 did not investigate the pos-
sible role of dietary determinants of plasma 
copeptin, because they did not include uri-
nary sodium and other osmolytes in the set 
of multivariate regression analyses. Th us, it 
is impossible to exclude that, at least in some 
individuals, a higher level of vasopressin 
secretion (that is, a higher level of plasma 
copeptin) was secondary to dietary habits 
characterized by high salt intake. In turn, the 
higher salt intake could be responsible for an 
elevation in vasopressin secretion via changes 
in plasma osmolarity on one hand, and in 
urinary albumin excretion on the other 
hand, as found in the Framingham Off spring 
Study. 9 Th e hypothetical pro-albuminuric 
eff ect of high salt intake could be mediated 
by an increase in glomerular pressure and / or 
a decrease in tubular reabsorption. 10 Th e role 
of inherited factors in this complex interplay 
is not defi ned but is proved by the observa-
tion that, within the population sample of 
the PREVEND Study, men had much higher 
levels of plasma copeptin and of urinary 
albumin excretion than women. 
 In conclusion, the observational study by 
Meijer  et al. 1 opens up a new frontier in the 
research area focusing on prevention and 
control of renal disease. Th e new set of data 
from the PREVEND Study supports the 
idea of a multifactorial regulation of urinary 
albumin excretion and puts forward the 
intriguing possibility that vasopressin 
should be added to the mosaic of the deter-
minants of microalbuminuria. Th is hypoth-
esis needs to be further investigated and 
confi rmed, but it is in keeping also with 
some data from intervention studies about 
the eff ects of the short-term administration 
of vasopressin analogs. Th e possible pro-
albuminuric role of vasopressin could also 
be investigated by interventional studies 
aiming to block the secretion of endogenous 
vasopressin or the effects of circulating 
vasopressin. At present, dietary interven-
tions consisting of an increased water intake 
or a decreased osmolyte intake appear as 
the only practical tools to reduce the secre-
tion of endo genous vasopressin. Th e use of 
vasopressin receptor antagonists represents 
hopefully a future option in the investiga-
tion of the blockade of vasopressin eff ects. 
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 Epidemiology of atherosclerotic 
renal artery stenosis as a mirror 
of prospective trials 
 Bernd  Krumme 1 
 Diagnosis and treatment of atherosclerotic renal artery stenosis (ARAS) in 
the elderly is a never-ending challenge for every nephrologist. Kalra  et al. 
report that adjusted hazard ratios for ARAS increased threefold from 
1992 to 2004 in 16 million United States Renal Data System participants 
aged 66 years or older. However, numbers of revascularizations showed a 
biphasic pattern with a declining number since 1999. These exciting data 
have to be discussed with the knowledge of recent prospective trials. 
 Kidney International (2010)  77, 6 – 8.  doi: 10.1038/ki.2009.326 
see original article on page 37
 Th e signifi cance of atherosclerotic renal 
artery stenosis (ARAS) for the clinical 
outcome of patients with hypertension 
and / or chronic kidney disease is still a 
matter of debate between nephro logists, 
interventional cardiologists, and radio-
logists. 1 There is no doubt about the 
increasing number of renal artery inter-
ventions over the past two decades in the 
United States as well as in Europe; how-
ever, the benefi t of these interventions 
remains a mystery. 2 Meanwhile, stenting 
of ARAS has been the treatment of choice 
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since the fi rst long-term results were pre-
sented by our group in 1997 3 ( Figure 1 ) 
and confi rmed by a randomized prospec-
tive study by van de Veen  et al. 4 
 At the beginning of this century, three 
randomized prospective trials with a lim-
ited number of patients in each single 
study did not show  per se any benefi t of 
intervention either for blood pressure 
outcome or for renal function. It is of note 
that meta-analysis of the three trials 
detected benefi cial eff ects of angioplasty 
on blood pressure, rather than on renal 
function. 5 Additionally, there was a 
trend toward a higher cardiovascular-
event rate in the group of patients who 
were treated exclusively by medication 
versus those who received angioplasty. 5 
However, since the publications of the 
three studies, many nephrologists favor 
a nihilistic approach of  ‘ no screen, no 
treat, ’ although up to now the number of 
preventable cardiovascular and renal 
events is unknown. 6 
 Th e report on atherosclerotic renovas-
cular disease by Kalra and co-workers 7 
(this issue), derived from the United 
States Renal Data System, mirrors the 
above-described process in a brilliant 
manner. Hazard ratios for the diagnosis 
of ARAS increased threefold from 1992 
to 2004 in patients aged 65 years or 
older. Th e reasons for this increasing inci-
dence can be manifold. Most likely, 
the growing use of noninvasive imaging 
techniques, such as magnetic resonance 
angio graphy, computer tomography 
angiography, and Doppler ultrasound, 
may be responsible for a better rate of 
detection of ARAS. Since the beginning of 
the 1990s, sensitivities and specifi cities of 
the imaging modalities have improved 
continuously, whereas functional tests, 
such as the captopril test or captopril scinti-
graphy, showed less accuracy. 8 
 It seems plausible that physicians look 
less frequently for ARAS in patients aged 
85 years or older with higher comorbidity, 
because of the lack of therapeutic conse-
quences. This might be the reason for 
the reduced adjusted hazard ratio of these 
patients suff ering ARAS in comparison 
with the general population in the study 
of Kalra  et al. 7 
 It is of note that the number of renal 
artery revascularizations presented in this 
study increased steadily from 1995 to 
1999, whereas it has decreased continu-
ously since 2000. 7 If one keeps in 
mind the data of the above-mentioned 
publications about renal artery interven-
tion, 3,4 it is likely that initial enthusiasm, 
derived from the primary study results, 
drove the rise of angioplasties with stent-
ing during the end of the 1990s. However, 
after publication of the prospective 
randomized DRASTIC trial in 2000, 9 in 
which medical treatment was shown to be 
as eff ective as angioplasty in patients with 
ARAS greater than 50 % , the number of 
interventions decreased continuously 
until now in the United States. 7 
 It will be of great interest in the near 
future to observe how the recently pub-
lished prospective randomized studies —
 such as the ASTRAL and STAR trials, 
both comparing the best medical plus 
interventional treatment of ARAS with 
the best medical treatment alone — will 
impact the therapeutic behavior of physi-
cians. 10,11 Although the ASTRAL trial, 
with 806 patients, is still ongoing, initial 
results have been published as an abstract 
at the American Society of Nephrology 
Renal Week 2008. Th e authors could not 
fi nd any eff ect of renal artery stent place-
ment on mortality, renal function, or 
blood pressure in patients with ARAS 
greater than 70 % . However, those patients 
who urgently needed renal artery revas-
cularization because of malignant hyper-
tension, fl uid lung, or rapidly developing 
renal failure were excluded from the study 
by their treating physicians (K. Wheatley 
 et al. , 2008, abstr. F-FC206; Renal Week, 
41st Annual Meeting and Scientifi c Expo-
sition, Philadelphia, Pennsylvania, USA, 
4 – 9 November 2008 ( http://www.asn-
online.org/press/Renal%20Week-08/14b-
Atherosclerosis-Wheatley.pdf )). 
 Th e STAR trial randomly assigned 140 
patients with ARAS greater than 50 % 
and impaired renal function (glomerular 
fi ltration rate >15 and   <  80  ml / min) for 
stent placement or medical treatment 
alone. Aft er 2 years there was no diff er-
ence between the two groups in the 
number of patients whose glomerular 
filtration rate fell by more than 20 % , 
which was the primary end point of the 
study. Cumulative survival was similar 
in the two groups. Again, patients with 
malignant hypertension were excluded 
from the study. 10 
 Now the epidemiological analysis of 
more than 16,000,000 patients in the 
United States, published by Kalra  et al. , 7 
shows signifi cantly lower adjusted hazard 
ratios for death of patients with ARAS 
who underwent renal revascularization 
compared with the tota l  group 
of patients with ARAS. Although this 
retrospective analysis contains a bias 
toward selection of healthier patients for 
revascularization, it is important to 
ask the authors of the recent prospective 
randomized trials some questions — for 
example, whether patient selection was 
representative in their trials. I feel that, 
because of ethical problems, both studies 
did not include patients with clini cally 
significant ARAS. Therefore interven-
tional treatment did not diff er from med-
ical treatment. 
 Figure 1  |  Stent placement in atherosclerotic ostial renal artery stenosis. 3 
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 Finally, we have to wait for the results 
of the CORAL trial, 11 the greatest study 
ever performed in the fi eld of renal artery 
intervention, which is currently testing 
medical treatment versus stent placement 
in 1080 patients with ARAS greater than 
60 % (pressure gradient >20  mm  Hg). Th e 
primary end point of this study will be car-
diovascular mortality. If this study presents 
signifi cant results, it is likely that epide-
miological data might change in fi ve years. 
Considering the recent results of the pro-
spective trial, nephrologists must be care-
ful to select those patients for interventional 
treatment of ARAS who urgently need 
revascularization of the renal artery. 
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